Chemistry and Materials Science Seminar: Dr. Kyle Rugg

Chemistry and Materials Science Seminar
Process Development of BI 1808128, A 4TH Generation EGFR Inhibtor
Dr. Kyle Rugg
Principal Scientist in Process Research at Boehringer Ingelheim Pharmaceuticals, Inc. in the Chemical Development Department

Zoom Registration Link

Abstract: The EGFR 4th Generation project aimed to treat non-small cell lung cancer patients exhibiting mutations that confer a resistance to available therapies. BI 1808128, a First-in-Class EGFR tyrosine kinase inhibitor (TKI) presented breakthrough therapeutic potential for such patients. Accordingly, the project had been given priority status with extremely aggressive development timelines, and simultaneously required large amounts of drug substance to be delivered. The process research and development toward BI 1808128 (and related compounds) will be described. Features of the synthetic route include the novel preparation of an imidazopyridine building block, and a challenging Buchwald-Hartwig amination.

Speaker Bio: Dr. Kyle Rugg is a Principal Scientist in Process Research at Boehringer Ingelheim Pharmaceuticals, Inc. in the Chemical Development Department. Raised in Vermont, Kyle received his B.S. and M.S. degrees in Chemistry from RIT in 2011 and 2013 respectively, where he performed research toward the total synthesis of eletefine under the direction of Prof. Jeremy Cody. Kyle then earned his Ph.D. in Chemistry from the University of Rochester in 2018 under the direction of Prof. Robert K. Boeckman, Jr., where he developed a second-generation total synthesis of (-)-nakadomarin A and synthetic methodologies toward (-)-apoptolidin A. Kyle began his industry career as a Senior Scientist in Process Research at Boehringer Ingelheim in Ridgefield, CT in 2018, where he has since led teams on developing the safe, economic, and scalable production of anticancer active pharmaceutical ingredients. Kyle earned the Boehringer Ingelheim President’s Award with his team in 2020 for providing accelerated drug substance supply. He has also been active in strategic outsourcing and CMO management, as well as various global strategic initiatives related to acceleration of development timelines. He was promoted to Principal Scientist in 2022.
 

Intended Audience: Undergraduates, graduates, experts. Those with interest in the topic.

To request an interpreter, please visit myaccess.rit.edu